Abstract
Background COVID-19 has been impacting on the whole world critically and constantly since late December 2019. Rapidly increasing infections has raised intense world-wide attention. How to model the evolution of COVID-19 effectively and efficiently is of great significance for prevention and control.
Methods We propose the multi-chain Fudan-CCDC model based on the original single-chain model in [8] to describe the evolution of COVID-19 in Singapore. Multi-chains can be considered as the superposition of several single chains with different characteristics. We identify parameters of models by minimizing the penalty function.
Results The numerical simulation results exhibit the multichain model performs well on data fitting. Though unsteady the increments are, they could still fall within the range of ±25% fluctuation from simulation results. It is predicted by multi-chain models that Singapore are experiencing a nonnegligible risk of explosive outbreak, thus stronger measures are urgently needed to contain the epidemic.
Conclusion The multi-chain Fudan-CCDC model provides an effective way to early detect the appearance of imported infectors and super spreaders and forecast a second outbreak. It can also explain the data in those countries where the single-chain model shows deviation from the data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Wenbin Chen is supported by the National Science Foundation of China (11671098, 91630309). Jin Cheng is supported in part by the National Science Foundation of China (11971121).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
